Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psychedelic therapy: does trip intensity matter?

NCT ID NCT07164287

Knowledge-focused Sponsor: University Hospital, Geneva Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at 376 patients who received psychedelic-assisted therapy with LSD or psilocybin for depression, anxiety, PTSD, or substance use disorders. Researchers want to see if the intensity of the psychedelic experience is linked to better outcomes. All data comes from past clinical records at a Swiss hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LSD or psilocybin
What this could lead to
If successful, this could help doctors understand how the intensity of a psychedelic session influences mental health outcomes, potentially guiding better treatment plans.
What could go wrong
This is a retrospective study, meaning it looks at past data, not a controlled experiment. Results may be less reliable and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 376 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Sep 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with treatment-resistant depressive, anxiety, or addictive disorders who received psychedelic-assisted psychotherapy under compassionate use authorization treated in the psychedelic-assisted psychotherapy program at Addiction Division, Department of Psychiatry, Geneva University Hospital, Switzerland.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients treated in the compassionate PAP program at Geneva University Hospitals between June 2020 and April 2025. * Diagnosis of depressive, anxiety, or addictive disorder resistant to standard treatments. * General consent for use of routinely collected clinical data. * Federal Office of Public Health authorization for PAP. Exclusion Criteria: * psychotic disorder * bipolar disorder * high suicidal risk * severe cardiovascular disease * severe liver disease * neurological disease of the central nervous system * pregnancy * breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder combat disorder major depressive disorder post-traumatic stress disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety disorders Major depressive disorder (MDD) PTSD - post traumatic stress disorder Substance use disorder (SUD)

Contacts and locations

Locations

  • Geneva University Hospital

    Geneva, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.